Lailai Yan1,2, Juntuo Zhou3, Dongfang Wang1, Dandan Si4, Yaqiong Liu1, Lijun Zhong5, Yuxin Yin6,7,8,9. 1. Department of Laboratorial Science and Technology, Vaccine Research Center, School of Public Health, Peking University, Beijing, 100191, China. 2. Medical and Health Analytical Center, Peking University Health Science Center, Beijing, 100191, China. 3. Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. 4. AB Sciex Analytical Instrument Trading Co., Ltd, Beijing Office, Beijing, 100015, China. 5. Medical and Health Analytical Center, Peking University Health Science Center, Beijing, 100191, China. zhonglijun@bjmu.edu.cn. 6. Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. yinyuxin@bjmu.edu.cn. 7. Medical and Health Analytical Center, Peking University Health Science Center, Beijing, 100191, China. yinyuxin@bjmu.edu.cn. 8. Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. yinyuxin@bjmu.edu.cn. 9. Beijing Key Laboratory of Tumor Systems Biology, Peking-Tsinghua Center for Life Sciences, Beijing, 100191, China. yinyuxin@bjmu.edu.cn.
Abstract
INTRODUCTION: Schizophrenia (SCH) is one of the most common psychiatric disorders, which involves impairments in motivation and cognition. The pathological mechanisms underlying SCH are still unknown, and no effective therapies can prevent or treat perfectly the cognitive impairments and deficit symptoms caused by SCH. OBJECTIVES: We aimed to find the lipid expression change in plasma that underlie SCH onset and antipsychotics treatment. METHODS: We performed a data independent acquisition-based untargeted lipidomic approach on a quadrupole-time of flight liquid chromatography coupled to mass spectrometry platform. The plasma lipidomic profiles of SCH patients (n = 20) pre- and post-antipsychotics treatment were acquired as well as healthy controls (n = 29). Grouped or paired t-test were used to analyze the data. RESULTS: Over 1000 features were detected by our lipidomic analysis, of which 445 lipids belonging to 17 lipid species were reliably identified by tandem mass spectrometry. After statistical analysis, 47 lipids belonging to 9 lipid species were found to be dysregulated between naive SCH patients and healthy controls, and 50 lipids belonging to 9 lipid species were found to be dysregulated after antipsychotics treatment. These findings include several new SCH-relevant lipid species such as sphingomyelin, acylcarnitine and ceramide. Four types of lipid expression regulative patterns can be concluded from the above mentioned findings, revealing information about mechanism, side-effect and potential target of antipsychotics. CONCLUSIONS: The work presented here have revealed several new lipid species which are significantly dysregulated in SCH disease development or antipsychotics treatment. These lipids provide new evidence for the pathological studies of SCH and new antipsychotics development, or can be considered as potentially candidate biomarkers for further validation.
INTRODUCTION:Schizophrenia (SCH) is one of the most common psychiatric disorders, which involves impairments in motivation and cognition. The pathological mechanisms underlying SCH are still unknown, and no effective therapies can prevent or treat perfectly the cognitive impairments and deficit symptoms caused by SCH. OBJECTIVES: We aimed to find the lipid expression change in plasma that underlie SCH onset and antipsychotics treatment. METHODS: We performed a data independent acquisition-based untargeted lipidomic approach on a quadrupole-time of flight liquid chromatography coupled to mass spectrometry platform. The plasma lipidomic profiles of SCH patients (n = 20) pre- and post-antipsychotics treatment were acquired as well as healthy controls (n = 29). Grouped or paired t-test were used to analyze the data. RESULTS: Over 1000 features were detected by our lipidomic analysis, of which 445 lipids belonging to 17 lipid species were reliably identified by tandem mass spectrometry. After statistical analysis, 47 lipids belonging to 9lipid species were found to be dysregulated between naive SCH patients and healthy controls, and 50 lipids belonging to 9lipid species were found to be dysregulated after antipsychotics treatment. These findings include several new SCH-relevant lipid species such as sphingomyelin, acylcarnitine and ceramide. Four types of lipid expression regulative patterns can be concluded from the above mentioned findings, revealing information about mechanism, side-effect and potential target of antipsychotics. CONCLUSIONS: The work presented here have revealed several new lipid species which are significantly dysregulated in SCH disease development or antipsychotics treatment. These lipids provide new evidence for the pathological studies of SCH and new antipsychotics development, or can be considered as potentially candidate biomarkers for further validation.
Authors: Robert S Plumb; Kelly A Johnson; Paul Rainville; Brian W Smith; Ian D Wilson; Jose M Castro-Perez; Jeremy K Nicholson Journal: Rapid Commun Mass Spectrom Date: 2006 Impact factor: 2.419
Authors: Julie Gauthier; Nathalie Champagne; Ronald G Lafrenière; Lan Xiong; Dan Spiegelman; Edna Brustein; Mathieu Lapointe; Huashan Peng; Mélanie Côté; Anne Noreau; Fadi F Hamdan; Anjené M Addington; Judith L Rapoport; Lynn E Delisi; Marie-Odile Krebs; Ridha Joober; Ferid Fathalli; Fayçal Mouaffak; Ali P Haghighi; Christian Néri; Marie-Pierre Dubé; Mark E Samuels; Claude Marineau; Eric A Stone; Philip Awadalla; Philip A Barker; Salvatore Carbonetto; Pierre Drapeau; Guy A Rouleau Journal: Proc Natl Acad Sci U S A Date: 2010-04-12 Impact factor: 11.205
Authors: Matej Orešič; Jing Tang; Tuulikki Seppänen-Laakso; Ismo Mattila; Suoma E Saarni; Samuli I Saarni; Jouko Lönnqvist; Marko Sysi-Aho; Tuulia Hyötyläinen; Jonna Perälä; Jaana Suvisaari Journal: Genome Med Date: 2011-03-23 Impact factor: 11.117
Authors: Joseph McEvoy; Rebecca A Baillie; Hongjie Zhu; Peter Buckley; Matcheri S Keshavan; Henry A Nasrallah; George G Dougherty; Jeffrey K Yao; Rima Kaddurah-Daouk Journal: PLoS One Date: 2013-07-24 Impact factor: 3.240